Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | SENTI-202 |
Synonyms | |
Therapy Description |
SENTI-202 comprises allogeneic NK-cells engineered to express a chimeric antigen receptor (CAR) targeting CD33 and FLT3 along with an inhibitory CAR (iCAR) targeting EMCN on healthy hematopoietic stem cells and progenitor cells, which potentially induces a cytotoxic immune response against tumor cells expressing CD33 and/or FLT3 (Cancer Res (2023) 83 (7_Supplement): 3195). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SENTI-202 | SENTI202|SENTI 202 | SENTI-202 comprises allogeneic NK-cells engineered to express a chimeric antigen receptor (CAR) targeting CD33 and FLT3 along with an inhibitory CAR (iCAR) targeting EMCN on healthy hematopoietic stem cells and progenitor cells, which potentially induces a cytotoxic immune response against tumor cells expressing CD33 and/or FLT3 (Cancer Res (2023) 83 (7_Supplement): 3195). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06325748 | Phase I | SENTI-202 | SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS | Recruiting | USA | AUS | 0 |